Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs

This publication has 18 references indexed in Scilit:

• Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
  Drug Metabolism and Disposition, 2002
• Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
  Journal of Clinical Oncology, 2002
• Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1
  Advanced Drug Delivery Reviews, 2001
• Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer
  International Journal of Radiation Oncology*Biology*Physics, 2000
• Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
  Cancer Chemotherapy and Pharmacology, 1999
• Expression of the Apical Conjugate Export Pump, Mrp2, in the Polarized Hepatoma Cell Line, Wif–B
  Hepatology, 1998
• The improved everted gut sac: a simple method to study intestinal P-glycoprotein
  International Journal of Pharmaceutics, 1998
• Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
  Clinical Pharmacology & Therapeutics, 1997
• Association of Intestinal Peptide Transport with a Protein Related to the Cadherin Superfamily
  Science, 1994
• Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
  Journal of Medicinal Chemistry, 1989